What Enfuvirtide is
Enfuvirtide is a peptide fusion inhibitor used in approved HIV treatment contexts.
Enfuvirtide is grouped under Approved / Clinical on PeptideFactCheck because it widens the peptide map into infectious-disease therapeutics and shows just how broad peptide medicine really is.
The useful starting point is to separate the molecule itself from the internet story around it. It widens the peptide map into infectious-disease therapeutics and shows just how broad peptide medicine really is.
Why people keep looking it up
It widens the peptide map into infectious-disease therapeutics and shows just how broad peptide medicine really is.
Enfuvirtide is a peptide fusion inhibitor used in approved HIV treatment contexts.
Enfuvirtide tends to stay in the conversation because it touches a familiar public theme: fusion inhibitor, hiv therapy, and peptide medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide antiviral with direct human evidence.
Human trials and official labeling support specific approved uses.
Mechanism follows viral entry inhibition and envelope-fusion biology.
Why this page carries the current tier: Approved peptide antiviral with direct human evidence.
The current seed trail for Enfuvirtide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a serious infectious-disease treatment context, not a generic wellness peptide.
FDA-approved enfuvirtide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Enfuvirtide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Enfuvirtide is CID 16130199. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16130199
- Formula
- C204H301N51O64
- Molecular weight
- 4492
- InChIKey
- PEASPLKKXBYDKL-FXEVSJAOSA-N
Matched synonyms include Enfuvirtide, 159519-65-0, Pentafuside, Fuzeon, DP178, DP-178, Enfuvirtida, CHEBI:608828.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Enfuvirtide returns 54 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Enfuvirtide returns 2410 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- T-20
- Generic names
- MIMULUS GUTTATUS WHOLE
- Routes
- SUBLINGUAL
- Application numbers
- Not linked
Indications and usage. INDICATIONS Fear or anxiety of a known origin.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.